Research programme: antimicrobial therapeutics - Amicrobe/University of California

Drug Profile

Research programme: antimicrobial therapeutics - Amicrobe/University of California

Alternative Names: Amicidin-α™; Amicidin-β™

Latest Information Update: 26 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amicrobe; University of California at Los Angeles
  • Developer Amicrobe
  • Class Anti-infectives; Antibacterials; Antifungals
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Infections

Most Recent Events

  • 24 Apr 2018 Amicrobe files for patent protection with Patent Cooperation Treaty for A-Blocks™
  • 24 Apr 2018 Amicrobe files for patent protection for the treatment of biofilms in United States, Japan, Australia and Mexico
  • 24 Apr 2018 Amicrobe has patent protection for antimicrobial materials in USA, Australia, Canada, Mexico, Singapore, Japan, and the European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top